The aim was to analyze quality-of-life (QOL) during the first year post transplant in 47 patients undergoing reduced-intensity conditioning (RIC) allotransplantation, and to compare these with a similar subgroup of patients receiving autologous stem cell transplantation (ASCT). We used self-reported questionnaires. Each answer scored from 0 (not at all) to 4 (very much), with higher scores indicating worse functioning. Mean value of physical categories among RIC transplants ranged between 1.23 and 0.77 indicating that patients scored very low for physical symptoms. Patients undergoing ASCT had higher scores in questionnaires performed early after transplant and then gradually improved (Po0.001). Overall, when we compared physical functioning scores, allo-RIC did significantly better (P ¼ 0.049). Nevertheless, while allo-RIC scores were significantly better for the first three questionnaires, ASCT patients did better in the last two questionnaires. These findings are in accordance with the toxicities observed in both subgroups which are lower in the RIC group early after transplant. No significant differences were observed between either subgroup for any of the functional, social/ family, psychological distress and satisfaction with doctor/nurse relationship items. We have observed similar QOL among patients undergoing RIC-allo as compared to ASCT although GVHD remains an important 'event' in QOL.
ditioning; nonmyeloablative; allogeneic transplant Patients' preferences are increasingly being considered in decision-making regarding treatment options, so that currently, no option should be pressed on patients without providing information about the potential benefits and harm. 1, 2 While choosing the best treatment option based on adequate evidence is possible for different diseases, 3, 4 risk groups of patients 5 or disease status, 6 evidence regarding outcome cannot always be offered. 2 In particular, considerations concerning outcome must take into account more than just patient survival. Moreover, even when there is sufficient evidence in terms of survival, issues regarding the long-term side-effects of intensive therapies are of tremendous importance for patients and their relatives, 7 especially when treatment options include aggressive therapeutic approaches. Unfortunately, although several studies have evaluated quality of life (QOL) of SCT recipients in recent years, information remains inconclusive. In this sense, while some authors have reported good physical and functional recovery after SCT, 8, 7, [9] [10] [11] other studies have described important functional impairments such as fatigue, psychological distress and sexual dysfunction. 12, 13 In addition, most of these studies are crosssectional, and other, longitudinal studies analyzing post transplant QOL over time are required.
14 Finally, previous cross-sectional studies have shown that QOL might be impaired after allogeneic transplantation more significantly than in autologous especially in the case of severe chronic graft versus host disease, [14] [15] [16] [17] [18] although as yet, there have been no longitudinal studies comparing QOL after autologous and allogeneic transplantation.
In an effort to reduce the morbidity and mortality associated with allogeneic transplantation, several groups have recently developed nonmyeloblative or reduced intensity conditioning regimens (RIC) designed to be immunosuppressive rather than myeloablative in order to reduce the toxicity associated with high-dose chemotherapy, while maintaining the therapeutic effect of the procedure through a graft versus leukemia reaction. 19, 20 These RIC transplants have extended the use of allogeneic transplantation to patients with a high risk of transplantrelated mortality (TRM) due to age or other concurrent medical conditions. 20 In the present study, for the first time, QOL was analyzed during the first year post transplant in patients undergoing RIC allogeneic transplantation, and we compared this cohort of patients with a similar group of patients receiving autologous SCT (ASCT) in the same institution during the same period of time. By definition, in our institution, patients with a suitable donor undergo RIC only in the event of advanced age or concurrent medical condition which increases the risk of morbidity and/or mortality after conventional myeloablative conditioning (CMC) regimen. For this reason, we did not compare RIC vs CMC since pretransplant characteristics of both subgroups of patients are significantly different, thus hampering any conclusion regarding comparison of QOL after transplantation. For this reason, we chose to compare RIC patients with a similar group of patients without a suitable donor undergoing ASCT. Moreover, ASCT is considered a procedure associated with a low morbidity and mortality thus making this subset of patients an interesting group to compare with RIC in terms of QOL. For this purpose, we used selfreported questionnaires 21 that patients completed at different time-points after transplant. Questionnaires meet requirements of validity, sensitivity and reliability for assessment of various issues such as physical, functional, psychological and social domains based on the FACT-BMT questionnaire.
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Patients and methods
Patients
Between January 1999 and January 2003, 47 out of 60 patients at our institution undergoing an RIC peripheral blood stem cell (PBSC) transplant (allo-RIC) from an HLA identical sibling, gave their consent to participate in this study. Patients gave written informed consent for inclusion in the protocol, which was approved by all local ethical review boards and the Spanish Drug Agency (protocol 99-0151). Eligibility criteria for entry into this RIC included patients with a myeloid or lymphoid malignancy potentially treatable with an allogeneic transplant, who were 45 years old or more and/or who were at high risk of transplantrelated mortality (TRM) according to their pretransplant evaluation. [24] [25] [26] [27] Patient characteristics are shown in Table 1 . Disease phase at transplant was categorized as early, low risk (acute leukemia or poor-risk myelodysplasia in first complete remission, first chronic-phase CML, lymphoid malignancy in first remission), intermediate (acute leukemia or myelodysplasia in second or more complete remission, second chronic or accelerated-phase CML, lymphoid malignancy in second or more remission, untreated standard-risk myelodysplasia) and advanced, high risk (refractory or relapsed acute leukemia or myelodysplasia, blastic-phase CML, refractory or relapsed lymphoid malignancy and all second transplants). Donors were sexmatched in 51% cases and mismatched in 49%.
Two RIC regimens based on fludarabine 150 mg/m 2 plus melphalan 140 mg/m 2 or fludarabine 150 mg/m 2 plus busulfan 10 mg/m 2 were used, the former regimen recommended for lymphoid and the latter for myeloid malignancies. 20 GVHD prophylaxis consisted of cyclosporine A (CsA) plus short-course methotrexate (MTX). Acute and chronic GVHD were graded by established criteria. 26 In addition, 70 out of 95 patients receiving autologous stem cell transplant (ASCT) during the same period who gave their consent to enter the study were included. Only patients to be monitored at our institution after the procedure were invited to enter the QOL study. Patient characteristics are shown in Table 1 . In all, 37 patients received BEAM 27 as the conditioning regimen. Other regimens used were: busulfan plus melphalan (eight patients), cyclophosfamide plus carboplatin plus thiotepa (six patients), melphalan (11 patients), busulfan plus cyclophosfamide (seven patients) and Cy plus TBI (one patient). 28, 29 Patients receiving RIC and ASCT received a mean of 2 vs 3 lines of chemotherapy prior to transplantation. While no significant differences were observed between the two groups in terms of median age, patients undergoing allo-RIC had a more advanced disease status as compared to those undergoing ASCT (21 vs 4% high-risk patients, respectively; Po0.001). In addition, significant differences were observed in terms of diagnosis (P ¼ 0.002, Table 1 ).
Quality of life assessment
Informed consent was required for the prospective QOL study. All eligible patients received the questionnaires on days þ 7, þ 14, þ 21, þ 90, þ 180, þ 270 and þ 360 post transplant. Questionnaires included 55 items divided into six domains assessing physical and functional environment, social/family well-being and psychological distress and satisfaction with the doctor/patient and nursery/patient relationship. Each answer was evaluated from 0 (not at all) to 4 (very much) with higher scores indicating worst functioning except for the items related to functional wellbeing and relationships (social and family well-being and patient/nurse or patient/doctor relationship) where higher scores indicate a better functioning. The questionnaire was based on FACT-BMT (version 3), [22] [23] [24] [25] including additional items regarding graft-versus-host-disease symptoms. 
Statistical analysis
In order to perform a longitudinal assessment of QOL during the first year after transplant, patients received the questionnaires at seven time points, as previously specified. For cross-sectional comparisons between values obtained at the different time points, univariate ANOVA tests were performed. For longitudinal comparisons, an intrasubject model (time) was defined in order to guarantee equivalence between groups, thereby configuring a mixed factorial or split-plot model 30, 31 in which the variability attributed to individual characteristics was eliminated by the maximum blocking design. 32 As a statistical model for the General Model Line, a two-way, Measurement Repeated Multiple Analysis (MR-MANOVA two way) was performed to compare the differences between both subgroups in terms of mean values considering the whole period analyzed, since the theoretical conditions (independence, normality, homoscedasticity, covariant equality and sphericity) were met and because the possible significance of the intrasubject factor (time) was sought in combination with the different Inter-subject factors.
All factors which significantly influenced QOL on univariate analysis were included in a multivariate analysis. Since the variables 'type of transplant' and 'graft versus host disease' are mutually exclusive (where 'type of transplant' ¼ 'autologous', GVHD does not apply), a multivariate analysis was performed including 'type of transplant,' but excluding GVHD and then a second multivariate analysis was performed which included GVHD but not the type of transplant.
As far as the validation of the questionnaire was concerned, items other than those already included in FACT-BMT, were selected and subjected to the Internal Validity of the Construct once the conditions necessary for the use of a Factorial Analysis were in place (sphericity test: P ¼ 0.000 and KMO ¼ 710). After confirming that the factors did not correlate between each other the Principal Components extraction method with Equamax rotation. In the last solution after rotation, three groups of variables were found which included items such as saturations superior to 0.515, which would account for the 61.483% total variability observed in the questionnaire. This led us to conclude that the Structural Validity of the scale had been sufficiently proven.
Results
Overall outcome
Although the number of CD34 þ cells infused did not significantly differ between either subgroup (2.3278.95 and 4.3872.41 s.d. Â 10 6 CD34 þ cells/kg for ASCT and allo-RIC, respectively; P ¼ 0.53), granulocyte engraftment was significantly faster among patients receiving autologous transplantation (Table 2 ). Both subgroups also differed regarding fever episodes (100 and 64% of patients receiving ASCT and RIC allogeneic transplant developed any fever episode, Po0.001) and finally, patients receiving ASCT had significantly more mucositis and nausea/vomiting as compared to patients receiving allo-RIC (Table 2) . No other severe toxicities were observed in either of the two groups.
With a median follow-up of 281 days (range: 21-2196 days) 17 patients have died and 17 have relapsed. Projected event-free survival (EFS) at 3 years is 51% for patients undergoing RIC allogeneic transplant and 54% for those receiving autologous transplantation and relapse rates did not significantly differ between either subgroup (21 vs 13%, ptns). Among allo-RIC patients acute graft versus host disease (aGVHD) appeared at a median of 35 days (range: 10-125) and an overall cumulative incidence was 42% (11% grades III-IV). Chronic GVHD flared at a median of 168 days (104-420) with overall cumulative incidence of 66%. All patients included in this study who developed aGVHD had extensive cGVHD.
Quality of life assessment (QOL)
Physical functioning categories. Regarding physical functioning categories, 13 items were analyzed. Mean values of physical categories among RIC allogeneic transplants ranged between 1.23 and 0.77, which indicates that, overall, patients scored very low for physical symptoms. As observed in Figure 1 , mean values did not significantly change during the year post transplant (P ¼ 0.34) in this subset of patients since scores were low even on the questionnaires performed very early after transplant in contrast to patients undergoing ASCT who had higher scores on questionnaires performed on days þ 7 to þ 28 and then gradually improved mean QOL scores at subsequent controls (scores ranging from 1.63 to 0.51, Po0.001). Overall, when we compared mean physical functioning scores during the first year after transplant between allo-RIC and ASCT patients, the former group did significantly better (Figure 1n , P ¼ 0.049). Nevertheless, it should be noted that while allo-RIC scores were better for the first three controls performed early after transplant, QOL in RIC allogeneic transplantation M Díez-Campelo et al patients undergoing autologous transplant did better in the last two questionnaires performed on days þ 270 and þ 365, so that both curves crossed around day þ 180, which coincides with the median day of cGVHD flare. More specifically, in the early post transplant period, patients undergoing ASCT had worse scores regarding lack of energy, need for rest, nausea, pain or symptoms related to therapy as specified in Figure 1a , c, d, f, g and h. This is in accordance with post transplant toxicities specified in Table 2 . Although scores decreased significantly later questionnaires for ASCT patients, overall, significant differences persisted in favor of allo-RIC patients in the longitudinal comparison during the first year post transplant regarding lack of energy, need of rest and nausea. By contrast, upon analyzing variables related to GVHD symptoms such as itching, ocular or mouth disturbances, we observed that, except for an initial benefit in mouth disturbances after allo-RIC, scores were significantly higher after day þ 180 among patients receiving RIC allogeneic transplant (Figure 1k, l, m) . Finally, on day þ 365, 9.5% of patients receiving allo-RIC, as compared to 5.5% among ASCT patients (P ¼ 0.54), scored 'quite a bit or very much' to the item 'I have shortness of breath,' while 32.3% of allo-RIC vs 59.1% of ASCT patients (P ¼ 0.01) scored 'quite a bit or very much' to the item 'I need to rest'.
Other variables with significant influence on mean physical well-being are summarized in Table 3 . Fever, mucositis and nausea/vomiting influenced physical wellbeing on days þ 7, þ 14 or þ 28, while none of them had an impact after that time-point in cross-sectional analysis. Nevertheless, mucositis and nausea/vomiting did influence the overall physical well-being during the first year post transplant as assessed by longitudinal analysis (Table 3 and Figure 2a, b) . In addition, as shown in Figure 2c and d, aGVHD adversely affects QOL in the cross-sectional analysis performed on the first four controls after transplant, while cGVHD had an unfavorable impact on QOL from day þ 180 and onwards. In the longitudinal analysis, GVHD significantly influenced QOL during the first year post transplant. All variables which significantly affected physical functioning on univariate longitudinal analysis were included in a multivariate analysis and mucositis plus type of transplant were the only variables which had a significant impact on physical well-being in the longitudinal analysis (P ¼ 0.0003 for both). By contrast, when we excluded type of transplant and included GVHD, this was the only variable which retained statistical significance in multivariate analysis (P ¼ 0.018).
Functional well-being categories. Eight items were included for evaluating functional well-being (see Appendix A). No significant differences were observed between either subgroup for any of the functional well-being items. Mean value of functional categories ranged between 2.03 and 2.52 among allo-RIC patients during the first year post transplant and between 2.04 and 2.75 among ASCT patients, so that in both groups mean scores slowly improved over the year post transplant. Nevertheless, 14.3% of allo-RIC and 26.3% of ASCT patients still had problems sleeping in the control performed on day þ 365 (P ¼ 0.29), while 38 vs 57.9% of allo-RIC and ASCT patients scored 'quite a bit or very much' to the item 'I'm able to work' (P ¼ 0.17). Table 3 Variables with significant influence on physical well-being during the first year post transplant 
Days after transplant Days after transplant
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Regarding variables which could influence mean functional well-being, only GVHD, both acute and chronic, had an adverse impact on functional well-being during the first year post transplant (Table 4) .
Social/family well-being and psychological distress categories. In total, 14 items divided into two domains were used to assess social/family well-being and psychological distress. Within the former domain, high scores (ie, better well-being for social and family items) were obtained for all questions (see Appendix A) even in the first controls performed early after transplantation, with mean scores ranging from 2.7 and 2.7 for ASCT and from 2.58 to 2.64 for allo-RIC in day þ 7 on day þ 365, respectively (P ¼ 0.29). In addition, no significant changes in mean scores were observed for these items during the year following transplant. By contrast, sexual well-being had low scores, ranging from 0.5 in the fist questionnaire to 2.2 in the questionnaire performed on day þ 365 (P ¼ 0.001). In fact, this was the only item which significantly improved during the first year post transplant. Finally, no significant differences were observed between ASCT and allo-RIC for any of these items.
Regarding psychological distress, seven items addressing symptoms of depression (see Appendix A) were evaluated. No significant differences were observed between patients undergoing ASCT or allo-RIC either in terms of depression or anxiety. Scores were low for depression and they did not significantly alter over the year post transplant. In this sense, 0-13% of allo-RIC and 4.3-23% of ASCT patients answered 'quite a bit or very much' to items related to depression in the first questionnaire (day þ 7) as compared to 5-5.6% of allo-RIC and 9-13.6% of ASCT patients in the questionnaire performed on day þ 365 (P40.63). Concerning symptoms of anxiety, again scores did not significantly alter during the year post transplant. Nevertheless, mean scores were slightly higher than those observed for depression with 22.6-45.2% of allo-RIC and 19-34.4% of ASCT patients who answered 'quite a bit or very much' to items related to anxiety in the first questionnaire (day þ 7) as compared to 26.3-44.4% of allo-RIC and 9.1-42.9% of ASCT patients in the questionnaire performed on day þ 365 (P40.14).
Doctor/patient and nurse/patient relationship. As far as relationship with doctors and nurses is concerned, all items were scored 3 or higher and no differences were observed between ASCT or allo-RIC patients. Scores did not significantly change during the year post transplant.
Discussion
Although allogeneic transplantation is the best treatment modality for patients diagnosed with poor prognostic acute leukemias or advanced stage hematological malignancies, 1, 3, 4 its efficacy has been hampered by significant morbidity and mortality related to the procedure (TRM). 33 Even with the chance of being cured, some questions remain crucial for these patients: Does the time gained have sufficient quality? Is curative therapy with a high mortality or persistent morbidity worth it? The answer to these questions should contribute to providing patients with better information regarding quality of life which would be of great use for patients and their physicians in standardizing practice regarding the decision-making process. Moreover, this information should be available to the patients and their relatives in order for them to choose the most appropriate treatment option. 2 With this goal in mind, in 1999, we developed a questionnaire based on FACT-BMT, [22] [23] [24] [25] including additional items regarding graft-versus-host-disease symptoms. The questionnaire was validated as previously described. We designed a prospective longitudinal study in order to evaluate the QOL among patients undergoing reduced intensity conditioning allogeneic transplantation and compared these results to those obtained among patients receiving ASCT.
RIC transplants have been developed to be immunosuppressive rather than myeloablative, 19, 20 in an effort to reduce the high mortality rate reported after conventional allogeneic transplantation in patients of advanced age or with comorbid pretransplantation conditions. 34 Moreover, in addition to a lower TRM, in standard clinical practice it has been observed that there is a significant improvement in QOL after RIC allogeneic transplantation although no study has been reported to date far evaluating the impact of this procedure on QOL of these patients. On the other hand, according to previous studies, age may adversely affect QOL after transplant and, since most candidates receiving RIC allogeneic transplantation are of advanced age or have a concurrent medical condition, QOL assessment could be impaired. 35 In addition, since this procedure may reduce TRM in patients with a poor performance status, a higher subset of these patients may survive after transplant thus adversely affecting overall QOL. Although it would be reasonable to argue that the optimal comparison in terms of QOL would have been to compare patients undergoing RIC vs conventional myeloablative conditioning (CMC) allogeneic transplantation, in our institution, patients with a suitable donor undergo RIC only in the event of advanced age or a comorbid medical condition which increases the risk of morbidity and/or mortality after conventional transplantation. For this reason, by definition pretransplant characteristics of both subgroups of patients are significantly different. An alternative was to compare RIC patients with a similar group of patients without a suitable donor undergoing ASCT in the same period of time. As a matter of fact, although some characteristics at transplant differ between the two subgroups, none of these variables represented a contraindication to receiving one or the other option and, furthermore, none of them significantly affected QOL on univariate analysis. In addition, this comparison would allow us to address the impact on QOL of the immune reactions inherent to the allogeneic transplant with low toxicity related to the chemotherapy in the RIC setting vs the side effects of the high doses of chemotherapy used in the autologous setting. Finally, ASCT is considered a procedure, which induces a low morbidity and mortality thus making this subset of patients an interesting group to compare with RIC in terms of QOL.
To the best our knowledge, the present study is the first of its kind to focus on QOL assessment after RIC allogeneic transplantation. Moreover, so far, there have been no longitudinal studies comparing QOL after autologous or allogeneic transplant especially during the first year after transplant, 12, 36 although cross-sectional studies have shown impaired QOL among patients receiving allogeneic as compared to those receiving autologous transplants mostly due to graft versus host disease-related symptoms. [14] [15] [16] [17] [18] In the present study, both subgroups of patients receiving either autologous or RIC allogeneic transplants had a similar median age although, as expected, diagnosis and disease status at transplant significantly differed between subgroups. Interestingly, when we compared physical well-being items, those patients receiving an RIC allogeneic transplant had a significantly better QOL during the first year post transplant, thus showing the favorable impact of RIC transplant on morbidity. Nevertheless, it should be noted that, in the current study, among seven questionnaires, four were completed before day þ 180 and only two after that date, so that the higher number of questionnaires completed during the first 6 months after transplant may have increased their weight in the overall comparison even though scores were better among patients receiving ASCT in the questionnaires performed after that date. Not unexpectedly, items concerning high-dose chemotherapy-related toxicity such as nausea and vomiting, lack of energy or need to rest had significantly better scores in the allo-RIC group than in the ASCT group. By contrast, symptoms related to acute graft versus host disease significantly hampered QOL among patients receiving RIC allogeneic transplants in the early post transplant period and symptoms related to chronic graft versus host disease adversely affected QOL after day þ 180, which was approximately the median day of cGVHD flare. In fact, items addressing cGVHD symptoms such as itching, ocular or mouth disturbances are variables which significantly contributed to the poorer QOL observed among allo-RIC patients after day þ 180, and thus effected the cross between the curves of ASCT and allo-RIC patients at that specific time-point. Although not surprising, this is an important finding since the therapeutic effect of allo-RIC transplantation relies mainly on the graft versus tumor effect and, in this sense, several studies have shown that cGVHD favorably affects event-free survival. 37 According to this and other studies, 11 cGVHD should also be considered an 'event' regarding QOL of patients, so that in the future, more specific targets for the immune response must be explored in order to exploit the graft versus tumor effect without hampering QOL.
Quality of life scores were good for most of the items analyzed; the same scores were found for ASCT and RIC patients regarding fuctional environment, social and family well-being, psychological distress and satisfaction with doctor/nurse relationships. Nevertheless, this information should be interpreted with caution since, as has been pointed out, 12, 38 patients who have suffered a stressful event, such as cancer diagnosis, are grateful for treatment, which would be reflected in their QOL scores. This could be a confusing variable in studies which have compared symptoms of patients receiving bone marrow transplantation with those of healthy controls. 39 By contrast, it would not affect either the comparison between ASCT and allo-RIC patients or the tendency or evolution of symptoms in patients during the year following transplant. In addition, it should be noted that, as suggested in previous studies, QOL among patients receiving a SCT is especially hampered during the first year post transplant, with improvements observed during the long-term follow-up for most patients at 2 and 5 years after transplantation. 7, 15 Interestingly, in our study, focusing on QOL during the first year post transplant, most patients gave low scores for fatigue or weakness, which are some of the most common symptoms described among SCT survivors. 12, 40 More specifically 9.5% of patients receiving allo-RIC scored 'quite a bit or very much' to the item 'I have shortness of breath' on day þ 365 which is in contrast to previous studies describing 72% of patients who reported distressing levels of fatigue at 20 months post transplant. 41 Although in the current study a significant proportion of patients (32.3% of allo-RIC) scored 'quite a bit or very much' to the item 'I need to rest' these results again compare favorably to previous studies showing that 30% of patients maintained problems with their energy level at 45 months post transplant. 40 Other symptoms commonly described after SCT are problems concerning sleep quality and psychological distress. 12, 40 In this sense, Whedon et al 42 have reported moderate-tosevere psychological distress in 93% of patients, while other authors have described symptoms of depression in 33-45% and anxiety in 48% of patients undergoing SCT. 43, 44 In the current study, 0-13% of patients undergoing RIC allogeneic transplantation showed symptoms of depression during the first year post transplant, which did not significantly differ from those patients undergoing autologous transplantation. By contrast, a higher percentage of patients had symptoms of anxiety, ranging from 22.6 to 45.2% among patients receiving allo-RIC and this incidence is similar to that reported in previous studies.
In the present study, we have observed a lower adverse impact on QOL of RIC allogeneic as compared to autologous transplantation during the first months after transplant, which is due to a lower incidence of high-dose chemotherapy-related toxicity. By contrast, graft versus host disease remains an important 'event' in terms of QOL among patients receiving RIC allogeneic transplant and its effect on QOL becomes evident at 9 months after transplantation. In conclusion, by the first time point in the decision-making process, impairment of QOL does not hamper the allo-RIC approach as compared to autologous transplantation at least in the period analyzed in the current study. Studies analyzing QOL of these patients in the long-term follow-up are warranted. 
